GuidelineJournal of the neurological sciences2020
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
Open access · bronzeAbstract readPractice Guideline
In one paragraph
Guideline in Journal of the neurological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 3 pooled it
12.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 3 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: A systematic review.Clinical neurology and neurosurgery · 2022Pooled it
- Management of Patients with Cerebellar Ataxia During the COVID-19 Pandemic: Current Concerns and Future Implications.Cerebellum (London, England) · 2020Guideline
- Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.Revue neurologique · 2020Guideline
- Effects of Plasma Exchange Combined with Immunoglobulin Therapy on Consciousness, Immune Function, and Prognosis in Patients with Myasthenia Gravis Crisis: A Prospective Randomized Test.Computational and mathematical methods in medicine · 2022Trial
- Management of patients with neurological diseases considering post-pandemic coronavirus disease 2019 (COVID-19) related risks and dangers - An updated European Academy of Neurology consensus statement.European journal of neurology · 2024Article
- Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19.BMC infectious diseases · 2024Article
- Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study.Frontiers in public health · 2024Article
- Predictive Factors for Poor Outcomes Associated with COVID-19 in a Retrospective Cohort of Myasthenia Gravis Patients.Journal of inflammation research · 2024Article
- Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study.Therapeutic advances in neurological disorders · 2024Article
- Health-related quality of life (HRQoL) and psychological impact of the COVID-19 pandemic on patients with myasthenia gravis.Intractable & rare diseases research · 2023Article
- A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases.Virology journal · 2023Review
- Impact of the COVID-19 pandemic on patients with myasthenia gravis: A survey of the Myasthenia Gravis Foundation of America MG patient registry.Muscle & nerve · 2023Article
- Clinical Characteristics of Myasthenia Gravis Patients with COVID-19 in Guangxi, China: A Case-Control Study.Journal of inflammation research · 2023Article
- Neuromuscular Disorders Associated With COVID-19.Neuroscience insights · 2023Review
- COVID-19 and myasthenia gravis: A review of neurological implications of the SARS-COV-2.Brain and behavior · 2022Review
- Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.European journal of neurology · 2022Article
- Article
- Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.Neurology(R) neuroimmunology & neuroinflammation · 2022Observational
- An Interesting Case of Fatal Myasthenic Crisis Probably Induced by the COVID-19 Vaccine.Cureus · 2022Article
- A Comprehensive Review of Neuromuscular Manifestations of COVID-19 and Management of Pre-Existing Neuromuscular Disorders in Children.Journal of clinical medicine · 2022Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 12 institutions in 6 countries.
International MG/COVID-19 Working Group
Saiju JacobDepartment of Neurology, Institute of Immunology and Immunotherapy, University Hospitals, Birmingham B15 2TH, United Kingdom. Electronic address: saiju.jacob@uhb.nhs.uk.
Srikanth MuppidiDepartment of Neurology, Stanford Neuroscience Health Center, Palo Alto, CA 94304, USA. Electronic address: muppidis@stanford.edu.
Amanda GuidonDepartment of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.
Jeffrey GuptillDepartment of Neurology, Duke University Medical Center, Durham, NC 27710, USA.
Michael HehirDepartment of Neurology, University of Vermont Medical Center, Burlington, VT 05401, USA.
James F HowardDepartment of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7025, USA.
Isabel IllaCatedràtica Neurologia U.A.B., Unitat Patologia Neuromuscular, Servei Neurologia, Hospital Santa Creu i Sant Pau, C/ Pare Claret 167, Barcelona 08025, Spain.
Renato MantegazzaDepartment of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milano, Italy.
Hiroyuki MuraiDepartment of Neurology, School of Medicine, International University of Health and Welfare, Narita, Japan.
Kimiaki UtsugisawaDepartment of Neurology, Hanamaki General Hospital, Japan.
John VissingDepartment of Neurology, 2082 Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Heinz WiendlDepartment of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany.
Richard J NowakDepartment of Neurology, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: richard.nowak@yale.edu.
Duke Medical Center · USFondazione IRCCS Istituto Neurologico Carlo Besta · ITHospital de Sant Pau · ESInternational University of Health and Welfare · JPMassachusetts General Hospital · USNational Hospital Organization Hanamaki Hospital · JPRigshospitalet · DKStanford Health Care · USUniversity of Münster · DEUniversity of North Carolina at Chapel Hill · USUniversity of Vermont Medical Center · USYale University · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MNCATS NIH HHS UL1 TR001863
Abstract
PubMed holds no abstract for this paper.
Indexed as
BetacoronavirusPandemicsClinical Trials as TopicCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDisease ManagementDisease SusceptibilityHumansImmunoglobulins, IntravenousImmunologic FactorsImmunosuppressive AgentsImmunotherapyLambert-Eaton Myasthenic SyndromeMyasthenia GravisPlasma ExchangeImmunoglobulins, IntravenousImmunologic FactorsImmunosuppressive AgentsVaccines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.